NEW YORK (GenomeWeb News) – Investment firm Mizuho late on Thursday upgraded Cepheid to a Buy rating, calling the Sunnyvale, Calif.-based molecular diagnostics firm "a best-in-class diagnostics company."

Analyst Peter Lawson upgraded Cepheid from a Neutral rating, although he lowered estimates to take into account potential lingering issues with the company's manufacturing capabilities, as well as a slower than expected uptake of new products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.